Guorong Ma: OmniNano Pharmaceuticals announce the execution of the Patent and Technology license with The University of Texas MD Anderson Cancer Center
Guorong Ma, Founding Chief Executive at OmniNano Pharmaceuticals, shared a post on LinkedIn:
“At OmniNano Pharmaceuticals (OmniNano), we are pleased to announce the execution of the Patent and Technology license with The University of Texas MD Anderson Cancer Center. The license grants OmniNano the rights to a novel polymeric drug delivery system. Such a system can deliver two drugs that work synergistically in improving efficacy and reducing toxicities for cancer treatments. Our lead drug candidate ONP-001 is initially targeted for treating pancreatic cancer (PDAC) and has shown remarkable anti-PDAC efficacy with a great safety profile, by killing tumor cells and depleting cancer stem cells, as well as modulating tumor micro-environment.
OmniNano is committed to develop innovative and effective therapies for treating PDAC and beyond. We are actively raising fund and welcome investments, to advance our treatment to the clinic to improve patient outcomes and extend their lives.”
Source: Guorong Ma/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023